Top

Published in:

01-10-2015 | Nuclear Medicine

Dual-time-point O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas

Authors: Philipp Lohmann, Hans Herzog, Elena Rota Kops, Gabriele Stoffels, Natalie Judov, Christian Filss, Norbert Galldiks, Lutz Tellmann, Carolin Weiss, Michael Sabel, Heinz Hubert Coenen, Nadim Jon Shah, Karl-Josef Langen

Published in: European Radiology | Issue 10/2015

Abstract

Objective

We aimed to evaluate the diagnostic potential of dual-time-point imaging with positron emission tomography (PET) using O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (¹⁸F-FET) for non-invasive grading of cerebral gliomas compared with a dynamic approach.

Methods

Thirty-six patients with histologically confirmed cerebral gliomas (21 primary, 15 recurrent; 24 high-grade, 12 low-grade) underwent dynamic PET from 0 to 50 min post-injection (p.i.) of ¹⁸F-FET, and additionally from 70 to 90 min p.i. Mean tumour-to-brain ratios (TBR_mean) of ¹⁸F-FET uptake were determined in early (20–40 min p.i.) and late (70–90 min p.i.) examinations. Time–activity curves (TAC) of the tumours from 0 to 50 min after injection were assigned to different patterns. The diagnostic accuracy of changes of ¹⁸F-FET uptake between early and late examinations for tumour grading was compared to that of curve pattern analysis from 0 to 50 min p.i. of ¹⁸F-FET.

Results

The diagnostic accuracy of changes of the TBR_mean of ¹⁸F-FET PET uptake between early and late examinations for the identification of HGG was 81 % (sensitivity 83 %; specificity 75 %; cutoff - 8 %; p < 0.001), and 83 % for curve pattern analysis (sensitivity 88 %; specificity 75 %; p < 0.001).

Conclusion

Dual-time-point imaging of ¹⁸F-FET uptake in gliomas achieves diagnostic accuracy for tumour grading that is similar to the more time-consuming dynamic data acquisition protocol.

Key Points

• Dual-time-point imaging is equivalent to dynamic FET PET for grading of gliomas.

• Dual-time-point imaging is less time consuming than dynamic FET PET.

• Costs can be reduced due to higher patient throughput.

• Reduced imaging time increases patient comfort and sedation might be avoided.

• Quicker image interpretation is possible, as no curve evaluation is necessary.

Available only for authorised users

Herholz K, Langen KJ, Schiepers C, Mountz JM (2012) Brain tumors. Semin Nucl Med 42:356–370PubMedCentralCrossRefPubMed

Heiss WD (2014) Clinical impact of amino acid PET in gliomas. J Nucl Med 55:1831–1841CrossRefPubMed

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294CrossRefPubMed

McConathy J, Yu W, Jarkas N, Seo W, Schuster DM, Goodman MM (2012) Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med Res Rev 32:868–905CrossRefPubMed

Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M et al (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 40:205–212PubMed

Swiss Agency for Therapeutic Products (2014) J Swissmedic 13:651

Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53:207–214CrossRefPubMed

Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K et al (2012) Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057CrossRefPubMed

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW et al (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687CrossRefPubMed

10.

Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H et al (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36:779–787CrossRefPubMed

11.

Pöpperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470

12.

Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J et al (2014) Intra-individual comparison of (1)(8)F-FET and (1)(8)F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol 16:434–440PubMedCentralCrossRefPubMed

13.

Moulin-Romsee G, D'Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L et al (2007) Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 34:2082–2087CrossRefPubMed

14.

Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K et al (2005) O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 32:422–429CrossRefPubMed

15.

Paulus W, Peiffer J (1989) Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64:442–447CrossRefPubMed

16.

Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J et al (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13:307–316PubMedCentralCrossRefPubMed

17.

Hamacher K, Coenen HH (2002) Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 57:853–856CrossRefPubMed

18.

Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A et al (2011) [German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]. Nuklearmedizin 50:167–173CrossRefPubMed

19.

Herzog H, Langen KJ, Weirich C, Rota Kops E, Kaffanke J, Tellmann L et al (2011) High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin 50:74–82CrossRefPubMed

20.

Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A et al (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36:841–847CrossRefPubMed

21.

Kim DW, Jung SA, Kim CG, Park SA (2010) The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med 35:400–403CrossRefPubMed

22.

Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Diez-Valle R, Tejada S et al (2011) Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med 52:865–872CrossRefPubMed

23.

Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al (2006) Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393–403PubMed

24.

Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W et al (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942CrossRefPubMed

25.

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S et al (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029CrossRefPubMed

26.

Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI et al (2012) Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. J Nucl Med 53:1367–1374CrossRefPubMed

Title: Dual-time-point O-(2-[18F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas
Authors: Philipp Lohmann
Hans Herzog
Elena Rota Kops
Gabriele Stoffels
Natalie Judov
Christian Filss
Norbert Galldiks
Lutz Tellmann
Carolin Weiss
Michael Sabel
Heinz Hubert Coenen
Nadim Jon Shah
Karl-Josef Langen
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 10/2015
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3691-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dual-time-point O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas

Abstract

Objective

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 10/2015

Prognostic CT and MR imaging features in patients with untreated extranodal non-Hodgkin lymphoma of the head and neck region

Longitudinal change in quantitative meniscus measurements in knee osteoarthritis—data from the Osteoarthritis Initiative

Clinical Feasibility of 3D Automated Coronary Atherosclerotic Plaque Quantification Algorithm on Coronary Computed Tomography Angiography: Comparison with Intravascular Ultrasound

Validation of a method to differentiate arterial and venous vessels in CT perfusion data using linear combinations of quantitative time-density curve characteristics

Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites

Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?